Skip to main content
OpenTrials
Completed

NCT Number: NCT00195286

Study Evaluating Piperacillin/Tazobactam in Complicated Urinary Infections.

The primary objective is to study the efficacy of piperacillin/tazobactam in patients with complicated urinary tract infections

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Urinary Infections

Age range

16 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Antequera (Málaga), Spain

Loading trial locations.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Hospitalized patients over 16 years of age with complicated urinary infection produced by bacteria that are suspected to be susceptible to treatment with Piperacillin-tazobactam.

Exclusion criteria

  • Patients known, or thought to be hypersensitivity to beta-lactams
  • Patients with an uncomplicated urinary tract infection

Treatment and study plan

Piperacillin/tazobactam

Drug

Sponsors and collaborators

Lead sponsor

Wyeth is now a wholly owned subsidiary of Pfizer

Industry

Registry information

Official study title

Study of the Safety and Efficacy of Piperacillin/Tazobactam in the Treatment of Patients With Complicated Urinary Infections.

Important dates

Study start
2004
Primary completion
2007
Study completion
2007
First posted
Sep 19, 2005
Registry last updated
Sep 25, 2009

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.